Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | The role of NK cells in preventing relapse in leukemia

Monika Holubová • 21 Mar 2022
EBMT 2022
Leukemia

Monika Holubová, PhD, Charles University Faculty of Medicine, Pilsen, Czech Republic, talks on the potential role of natural killer (NK) cells in relapse control after haploidentical stem cell transplantation (SCT) in leukemia. Following treatment, tumor cells are damaged and express stress-associated molecules which allow them to be recognized and killed by NK cells. The success of this mechanism is variable. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Monika Holubová

1:57
Perspectives on allogeneic NK cell-based immunotherapy
Monika Holubová • 21 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals